![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
National Cancer Center, Korea |
---|---|
Information provided by: | National Cancer Center, Korea |
ClinicalTrials.gov Identifier: | NCT00735566 |
Endogenous antiangiogenic factors are related with gastric cancer progression.
Condition |
---|
Gastric Cancer |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression |
Serum for protein assay using ELISA
Estimated Enrollment: | 240 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | January 2012 |
Estimated Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Gastric cancers have been known to secrete the proangiogenic cytokine VEGF in vitro and in vivo. Tumor VEGF expression is correlated with the severity of disease in patients with gastric cancer and some authors have suggested using circulating VEGF as a prognostic factor or tumor marker.In addition to producing proangiogenic cytokines, recent data demonstrate that tumors can produce antiangiogenic cytokine as well. It has been suggested that, in humans, the generation of antiangiogenic compounds in the presence of a primary tumor suppresses the growth of distant metastases. This phenomenon has been demonstrated in mice and in patients with clear cell renal cancer, breast cancer, and colorectal cancer. However, the presence of endogenous antiangiogenic cytokines in patients with gastric cancer has not been reported.
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Eligible patients will undergo subtotal or total gastrectomy with D2 lymph node dissection
Inclusion Criteria:
Exclusion Criteria:
Contact: Jun Ho Lee, M.D., Ph.D | 82-31-920-1629 | kosmas@ncc.re.kr |
Korea, Republic of, Geonggi-do | |
National Cancer Center | Recruiting |
Goyang-si, Geonggi-do, Korea, Republic of, 410-0769 | |
Contact: Jun Ho Lee, M.D., Ph.D 82-31-920-1629 kosmas@ncc.re.kr |
Principal Investigator: | Jun Ho Lee, M.D., Ph.D | Gastric Cancer Branch, National Cancer Center |
Principal Investigator: | Jun Ho Lee, M.D., Ph.D | Gastric Cancer Branch, National Cancer Center |
Responsible Party: | National Cancer Center ( Jin Soo Lee/President ) |
Study ID Numbers: | NCCCTS 04-105 |
Study First Received: | August 13, 2008 |
Last Updated: | August 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00735566 |
Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
gastric cancer antiangiogenic factors TNM stage |
Stomach Diseases Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases |
Stomach Neoplasms Disease Progression Gastrointestinal Neoplasms Stomach cancer |
Neoplasms Neoplasms by Site |